CD33 and acute lymphoblastic leukemia: Interestingly, the lineage switch of B lymphocytes from the lymphoid lineage to the myeloid lineage can be seen in patients with B-ALL who experienced CD19-directed immunotherapy in which CD19 expression was lost while myeloid marker levels such as CD33 were upregulated [124, 125].